

For Immediate Release

CyGenics to List CordLife

22nd November 2005 – Leading cell therapy company CyGenics Ltd. (ASX: CYN), today announced its intention to investigate the listing of its tissue banking business, predominantly held under its subsidiary, CordLife Pte Ltd, on a key Asian stock exchange.

The listing seeks to raise additional funds for both investment and working capital, and would create an attractive second equity position for existing and potential shareholders.

The separate listing would enable CordLife to interact directly with the Asian financial markets and to accelerate international expansion plans for the tissue banking business.

“The company has been successful in replicating its business model in several markets and is now embarking on an aggressive expansion plan. Such a listing would provide an opportunity to accelerate growth and unlock shareholder value,” said Mr Chris Fullerton, Chairman of CyGenics.

About CordLife

CordLife is a regional cord blood bank that operates a state-of-the-art AABB (formerly known as the American Association of Blood Banks) accredited facility in Singapore and a separate compliant facility in Hong Kong. The company currently has business activities in Australia, Singapore, Hong Kong, Indonesia, Philippines and Thailand. CordLife is a wholly-owned subsidiary of CyGenics. The first private cord blood bank to be set up in Singapore, and among the first in Asia, CordLife’s start-of-the-art facility is the first in Southeast Asia to be accredited by AABB, and is the only bank to be so accredited in this region. These banking facilities comprise full processing and cryogenic storage capabilities. For further information, please visit www.cordlife.com.

About CyGenics

CyGenics is a cell therapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates four subsidiaries: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in Boston, USA, and CytoVations (new product development) based in New Jersey, USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.



For more information, please contact:

General Inquiries

Steven Fang, CEO, CyGenics Ltd Mob: +61 (0)400 933 243 Email: steven.fang@cygenics.com	Ian Brown, COO, CyGenics Ltd Mob: +61 (0)438 565 212 Email: ian.brown@cygenics.com
--	--

Media Inquiries

Rebecca Piercy, Buchan Consulting Ph: +61 (0)3 9866 4722 Mob: +61 (0)422 916 422 Email: rpiercy@bcg.com.au	Ronald Hee, CyGenics Ltd Ph: +65 6238 0808 Mob: +65 9061 9098 Email: ronald.hee@cygenics.com
---	---